CUSIP 31189P102 · who reports it, how much, and how much it matters to them
15 of the 720 hedge fund managers we track reported shares of Fate Therapeutics Inc (Nasdaq: FATE) on Form 13F for 30 June 2026. Between them they reported USD 66m. The largest position belongs to Redmile Group, at USD 35m.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Redmile Group10 funds on PPLI.com | USD 35m | 2.3% |
| 2 | Two Sigma Investments35 funds on PPLI.com | USD 9.7m | 0.0% |
| 3 | Renaissance Technologies13 funds on PPLI.com | USD 8.1m | 0.0% |
| 4 | Millennium Management6 funds on PPLI.com | USD 6.6m | 0.0% |
| 5 | Citadel Advisors32 funds on PPLI.com | USD 2.7m | 0.0% |
| 6 | Dafna Capital Management6 funds on PPLI.com | USD 1.4m | 0.3% |
| 7 | Marshall Wace LLP84 funds on PPLI.com | USD 1.3m | 0.0% |
| 8 | POINT72 Asset Management17 funds on PPLI.com | USD 1.2m | 0.0% |
| 9 | Squarepoint Ops7 funds on PPLI.com | USD 415,000 | 0.0% |
| 10 | Schonfeld Strategic Advisors30 funds on PPLI.com | USD 179,000 | 0.0% |
| 11 | Hudson Bay Capital Management8 funds on PPLI.com | USD 67,932 | 0.0% |
| 12 | Bronte Capital Management Pty3 funds on PPLI.com | USD 58,698 | 0.0% |
| 13 | Graham Capital Management18 funds on PPLI.com | USD 38,202 | 0.0% |
| 14 | Balyasny Asset Management25 funds on PPLI.com | USD 36,215 | 0.0% |
| 15 | The Quarry1 fund on PPLI.com | USD 689 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Redmile Group | USD 35m | 2.3% |
| 2 | Dafna Capital Management | USD 1.4m | 0.3% |
| 3 | Renaissance Technologies | USD 8.1m | 0.0% |
| 4 | Two Sigma Investments | USD 9.7m | 0.0% |
| 5 | Bronte Capital Management Pty | USD 58,698 | 0.0% |
| 6 | Millennium Management | USD 6.6m | 0.0% |
| 7 | Marshall Wace LLP | USD 1.3m | 0.0% |
| 8 | POINT72 Asset Management | USD 1.2m | 0.0% |
| 9 | Schonfeld Strategic Advisors | USD 179,000 | 0.0% |
| 10 | Graham Capital Management | USD 38,202 | 0.0% |
Fate Therapeutics Inc trades under the symbol FATE on the Nasdaq. Its CUSIP, the code used on Form 13F, is 31189P102.
15 of the 720 hedge fund managers PPLI.com tracks reported Fate Therapeutics Inc shares on Form 13F for 30 June 2026. The largest reported positions were held by Redmile Group (USD 35m), Two Sigma Investments (USD 9.7m), Renaissance Technologies (USD 8.1m), Millennium Management (USD 6.6m) and Citadel Advisors (USD 2.7m).
15 managers in our coverage reported it, and between them they run 295 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Redmile Group, where the position was 2.3% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with Fate Therapeutics Inc or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.